Skip to content
Head to head

Mesoblast vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: MESO · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

MESO -27.8%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
MESOVRTX
Snapshot
Sector--Biotechnology
Last price10.89515.02
Change today-2.59%-1.08%
1-year return-24.0%+22.0%
Market cap$1.42B$130.58B
52-week range10.87 – 21.50412.27 – 568.67
Valuation
P/E (TTM)-24.7533.14
P/E percentile, own 5-yr range4th99th
P/B2.496.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.4415.32
Net profit (TTM)$-57.24M$3.88B
Revenue (TTM)$7.50M$12.95B
Provider revenue period date2023-06-292026-09-29
Revenue growth (YoY)-3.8%+11.8%
Gross margin86.1%85.5%
Operating margin-42.6%33.1%
Net margin-47.8%30.7%
Free cash flow (TTM)$-31.81M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership28.8%96.8%
Insider activity (12mo)1 buy / 0 sell28 buy / 22 sell
Short interest (% of float)2.8%1.9%
Analyst consensus100% buy (2)95% buy / 5% hold (21)
Analyst price target$37 (+240%)$624 (+21%)
StockVane view
StockVane Quant RatingD (16)C (68)
Company
Employees1086,400
Founded20041989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.